Mainz Biomed (NASDAQ:MYNZ – Get Free Report)’s share price fell 5.7% during mid-day trading on Monday . The company traded as low as $0.21 and last traded at $0.23. 3,189,528 shares changed hands during trading, an increase of 158% from the average session volume of 1,236,763 shares. The stock had previously closed at $0.24.
Mainz Biomed Stock Performance
The company’s fifty day simple moving average is $0.26 and its two-hundred day simple moving average is $0.41. The stock has a market capitalization of $2.69 million, a P/E ratio of -0.14 and a beta of 0.07.
Mainz Biomed Company Profile
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
Featured Articles
- Five stocks we like better than Mainz Biomed
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- Investing in Travel Stocks Benefits
- Williams-Sonoma Stock: Buy It and Never Let It Go
- Best Aerospace Stocks Investing
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
